Clinical Trial Update: Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer [Phase 2]

View source ↗

Summary

Termination of a Phase 2 trial of imatinib mesylate in progressive, refractory, or recurrent stage II/III testicular or ovarian germ cell tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Dysgerminoma
• Ovarian Germ Cell Tumor
• Testicular Germ Cell Tumor
• Testicular Seminoma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor | Phase 2 | Status: TERMINATED